Dual GIP and GLP-1 Receptor Agonist Peptide Tirzepatide for Hyperglycemia Reduction

Dual GIP and GLP-1 Receptor Agonist Peptide Tirzepatide for Hyperglycemia Reduction

Product desciption:

Tirzepatide is administered subcutaneously via an injection. It is not available in oral form at this time.

It is available in various dosages: 2.5 mg/0.5 mL, 5 mg/0.5 mL, 7.5 mg/0.5 mL, 10 mg/0.5 mL, 12.5 mg/0.5 mL, 15 mg/0.5 mL. Standard dosing is once weekly, with the usual initiation dose being 5 mg/0.5 mL. Prescribed doses can be increased on follow-up visits based on efficacy, as defined by hemoglobin A1C levels and body weight, and adverse effects. The primary adverse drug reactions are largely gastrointestinal related, such as abdominal discomfort and nausea, with variable severity. The patients' ability to tolerate side effects plays a significant role in the titration of tirzepatide dosing.

Use in Specific Patient Population

Patients with Hepatic Impairment: According to the manufacturer's product information, no dosage adjustment of tirzepatide is suggested for patients with hepatic impairment.

Patients with Renal Impairment: No dosage adjustment of tirzepatide is suggested for patients with hepatic impairment. However, tirzepatide is associated with gastrointestinal ADRs, including nausea, vomiting, and diarrhea leading to dehydration, which can cause acute kidney injury. Use with caution in patients prone to dehydration.

Related products:

Product Photos:

Certifications:

Company:

FAQ: